Skip to main content
SpringerLink
Log in

A balloon is better than diet: the role of lifestyle changes in the management of obesity and steatotic liver, and need for a winning strategy

  • IM - COMMENTARY
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable.

References

  1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335–1347

    Article  PubMed  Google Scholar 

  2. Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH (2023) Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. https://doi.org/10.1038/s41575-023-00800-4

    Article  PubMed  Google Scholar 

  3. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438

    CAS  PubMed  Google Scholar 

  4. Portincasa P (2023) NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med 18:993–1006

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mendez-Sanchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH et al (2022) Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 7:388–390

    Article  PubMed  Google Scholar 

  6. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. https://doi.org/10.1097/HEP.0000000000000520

    Article  PubMed  Google Scholar 

  7. Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S et al (2020) MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 40:3018–3030

    Article  CAS  PubMed  Google Scholar 

  8. Scheinberg AR, John BV (2022) MAFLD versus NAFLD: Which better predicts the risk of atherosclerotic cardiovascular disease? Dig Dis Sci 67:4606–4608

    Article  PubMed  Google Scholar 

  9. Zhao Q, Deng Y (2023) Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol. https://doi.org/10.1016/j.jhep.2023.08.003

    Article  PubMed  Google Scholar 

  10. van Dijk A, de Vries M, El-Morabit F, Bac ST, Mundt MW, van der Schuit LE et al (2023) Intra-gastric balloon with lifestyle modification a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease. Intern Emerg Med. https://doi.org/10.1007/s11739-023-03417-2. (in press)

    Article  PubMed  PubMed Central  Google Scholar 

  11. Shah RH, Vedantam S, Kumar S, Amin S, Pearlman M, Bhalla S (2023) Intragastric balloon significantly improves metabolic parameters at 6 months: a meta-analysis. Obes Surg 33:725–732

    Article  PubMed  Google Scholar 

  12. Molina-Molina E, Shanmugam H, Di Ciaula A, Grattagliano I, Di Palo DM, Palmieri VO, Portincasa P (2021) ((13)C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle. JHEP Rep 3:100203

    Article  PubMed  Google Scholar 

  13. Abbitt D, Netsanet A, Kovar A, Choy K, Jones TS, Cassell B et al (2023) Losing weight to achieve joint or hernia surgery: is the intragastric balloon the answer? Surg Endosc 37:7212–7217

    Article  PubMed  Google Scholar 

  14. Foula MS, Amer NM, Zakaria H, Ismail MH, Alshomimi SJ, Al Bisher HM et al (2023) Surgical management of intra-gastric balloon complications, single-center experience, and literature review. Obes Surg 33:2718–2724

    Article  PubMed  Google Scholar 

  15. Oster M, Hein N, Aksan A, Krammer H, Theodoridou S, Stein J (2023) Efficacy and safety of intragastric balloon therapy compared to a multidisciplinary weight loss program (OPTIFAST) in a real-world population: a propensity score matching analysis. Obes Facts 16:89–98

    Article  PubMed  Google Scholar 

  16. Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y et al (2019) Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing diabetes prevention outcome study. Lancet Diabetes Endocrinol 7:452–461

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kim ER, Park JS, Kim JH, Oh JY, Oh IJ, Choi DH et al (2022) A GLP-1/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome. Hepatology 75:1523–1538

    Article  CAS  PubMed  Google Scholar 

  18. Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B et al (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398:2160–2172

    Article  CAS  PubMed  Google Scholar 

  19. Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S et al (2023) Triple-hormone-receptor agonist retatrutide for obesity-a phase 2 trial. N Engl J Med 389:514–526

    Article  CAS  PubMed  Google Scholar 

  20. Di Ciaula A, Bonfrate L, Khalil M, Garruti G, Portincasa P (2023) Contribution of the microbiome for better phenotyping of people living with obesity. Rev Endocr Metab Disord 24(5):839–870

    Article  PubMed  Google Scholar 

  21. Di Ciaula A, Portincasa P (2019) Diet and contaminants: driving the rise to obesity epidemics? Curr Med Chem 26:3471–3482

    Article  PubMed  Google Scholar 

  22. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. https://doi.org/10.1016/j.jhep.2023.06.003

Download references

Author information

Authors and Affiliations

  1. Clinica Medica “A. Murri”, Department of Preventive and Regenerative Medicine and Ionian Area (DiMePrev-J), University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124, Bari, Italy

    Agostino Di Ciaula & Piero Portincasa

Authors
  1. Agostino Di Ciaula
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piero Portincasa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agostino Di Ciaula.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Ciaula, A., Portincasa, P. A balloon is better than diet: the role of lifestyle changes in the management of obesity and steatotic liver, and need for a winning strategy. Intern Emerg Med 19, 5–7 (2024). https://doi.org/10.1007/s11739-023-03448-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-023-03448-9

Search

Navigation